Arimoclomol: a potential therapy under development for ALS
Authors:
- Scott WielandSWScott Wieland
- Jack BarberJBJack Barber
- Merit CudkowiczMCMerit Cudkowicz
- 23 October 2009
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 18 (12) , 1907-1918
Abstract
Arimoclomol, an amplifier of heat shock protein expression involved in cellular stress response, has emerged as a potential therapeutic candidate in amyotrophic lateral sclerosis (ALS) in recent years. Treatment with arimoclomol was reported to improve survival and muscle function in a mouse model of motor neuron disease. Several single- and multiple-dose safety studies have been completed in healthy control subjects. A 3-month Phase IIa study in people with ALS demonstrated safety at dosages up to 300 mg/day and another study is currently recruiting participants with familial ALS caused by mutations in the superoxide dismutase gene. We review the rationale for testing arimoclomol in sporadic and familial ALS in the context of available safety and pharmacokinetic data. Published and unpublished literature relative to the drug in the past two decades is discussed. The current review attempts to bring together our existing understanding of the actions of arimoclomol with the disease profile of ALS. The phar...Keywords
This publication has 77 references indexed in Scilit:
- TDP-43 Is Intrinsically Aggregation-prone, and Amyotrophic Lateral Sclerosis-linked Mutations Accelerate Aggregation and Increase ToxicityJournal of Biological Chemistry, 2009
- Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathiesActa Neuropathologica, 2009
- Neuropathy Target Esterase Gene Mutations Cause Motor Neuron DiseaseThe American Journal of Human Genetics, 2008
- Early use of non‐invasive ventilation prolongs survival in subjects with ALSAmyotrophic Lateral Sclerosis, 2007
- A Mutation in the Vesicle-Trafficking Protein VAPB Causes Late-Onset Spinal Muscular Atrophy and Amyotrophic Lateral SclerosisThe American Journal of Human Genetics, 2004
- Decrease of Hsp25 protein expression precedes degeneration of motoneurons in ALS‐SOD1 miceEuropean Journal of Neuroscience, 2004
- Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trialsAmyotrophic Lateral Sclerosis, 2004
- Protein aggregation in motor neurone disordersNeuropathology and Applied Neurobiology, 2003
- Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1Biochemical and Biophysical Research Communications, 2003
- Mutant dynactin in motor neuron diseaseNature Genetics, 2003